NON-SMALL CELL LUNG CANCER ALK-POSITIVE

Clinical trials for NON-SMALL CELL LUNG CANCER ALK-POSITIVE explained in plain language.

Never miss a new study

Get alerted when new NON-SMALL CELL LUNG CANCER ALK-POSITIVE trials appear

Sign up with your email to follow new studies for NON-SMALL CELL LUNG CANCER ALK-POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Researchers review how lorlatinib works in everyday chinese lung cancer patients

Knowledge-focused Ongoing

This study looks back at medical records of 50 Chinese adults with ALK-positive advanced non-small cell lung cancer who started treatment with the drug lorlatinib. The goal is to understand patient characteristics and how the drug is used in real-world settings. No new treatments…

Matched conditions: NON-SMALL CELL LUNG CANCER ALK-POSITIVE

Sponsor: Pfizer • Aim: Knowledge-focused

Last updated May 17, 2026 01:59 UTC

NON-SMALL CELL LUNG CANCER ALK-POSITIVE

Get alerted when new NON-SMALL CELL LUNG CANCER ALK-POSITIVE trials appear

Researchers review how lorlatinib works in everyday chinese lung cancer patients